Key FDA reform bills could be undermined by pre-emption clause
This article was originally published in Clinica
US House Democrats drafted a package of Food and Drug Administration reform bills late last week that included a few tiny lines that caused a big fuss at a hearing on Tuesday June 12. Those lines would prohibit FDA law from pre-empting state court damage claims that opponents say could potentially jeopardise passage, writes April Fulton.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.